Nanoligent closes €12 million Series A financing to advance its lead oncology nanodrug
Nanoligent is proud to announce the completion of a €12 million Series A financing round led by Inveready (Inveready Biotech IV), with participation from CDTI (through the Innvierte program), Clave Capital (Clave Innohealth), and existing investors i&i Biotech Fund I, Italian Angels for Growth / Nanolinvest, and AVANTECA Partners. The proceeds will support completion of […]
Nanoligent wins the Santander X Award for Best UAB’s University Start-up
We are proud to announce that Nanoligent has won the Santander X Award 2025 in the category of Best University Start-up from UAB, at the awards ceremony held on June 19th at the Universitat Autònoma de Barcelona (UAB). This award, promoted by Banco Santander and Emprèn UAB, recognizes entrepreneurial projects with high social and economic […]
Call of the ordinary general shareholders meeting of the company Nanoligent, S.L.
ENGLISH The Board of Directors of Nanoligent, S.L. has convened the Ordinary General Shareholders Meeting to be held on June 11, 2025, at 10:00 a.m. The meeting will take place at the Barcelona Chamber of Commerce, Diagonal 452, 2nd floor, in Barcelona. In compliance with the Capital Companies Act, shareholders may access all documentation related […]
